The drug was also shown not to be inferior to Johnson & Johnson's Stelara in helping symptoms of the disease disappear. Lilly said frequency of serious adverse events was greater in placebo than with patients dosed with mirikizumab. In April, the U.S. Food and Drug Administration (FDA) had declined to approve use of the drug in adults with ulcerative colitis, a type of chronic inflammatory bowel disease.
SARS-CoV-2 infection may elevate risk for certain autoimmune disorders, suggests study. Regular post-COVID monitoring needed to detect and manage potential autoimmune consequences.